Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells

At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezom...

Full description

Bibliographic Details

Published in:	Cells
Main Authors:	Margot S.F. Roeten, Johan van Meerloo, Zinia J. Kwidama, Giovanna ter Huizen, Wouter H. Segerink, Sonja Zweegman, Gertjan J.L. Kaspers, Gerrit Jansen, Jacqueline Cloos
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Subjects:	leukemia proteasome proteasome inhibitor ixazomib BTZ resistance drug resistance
Online Access:	https://www.mdpi.com/2073-4409/10/3/665